T-Rex leather handbags could be made using fossil DNA
T-Rex leather accessories could be available by the end of the year.
Lab-Grown Leather, based in Newcastle, teamed up with The Organoid Company to grow extinct hides using dinosaur DNA.
A full-length collagen sequence will be generated for the dinosaur, which will be used to grow new skin.
Until recently, it was thought dinosaur DNA would be impossible to find because the fragile strands do not survive over tens of millions of years.
However, in the past decade, paleobiologists found collagen preserved in dinosaur fossils, including an 80 million-year-old Tyrannosaurus Rex.
'Innovative and ethically sound'
In 2023, Lab-Grown Leather became the first biotech company to successfully culture fully natural animal skin, and now believes it can use its technology to recreate T-Rex hide. The team believes the leather will be tough and durable, and hopes to have its first product available by the end of the year.
Prof Che Connon, of Lab-Grown Leather, said: 'We're unlocking the potential to engineer leather from prehistoric species, starting with the formidable T-Rex. This venture showcases the power of cell-based technology to create materials that are both innovative and ethically sound.'
Lab-Grown Leather was the first to create animal skin without using a scaffold to coax the tissue into the correct alignment. Instead, scientists managed to recreate the biochemical and biophysical cues that occur in the body to make the cells spontaneously arrange themselves in the correct pattern.
It means that there is no need to use animal-derived serums to help kick off the growth process or blends and fillers that other synthetic meat and skin companies need, which prevents products from feeling natural.
Without the need of artificial scaffolds or fillers, the leather that is produced is 100 per cent animal tissue, without any extra animal products.
To create T-Rex leather, the team plans to piggyback on recent research that extracted a fragment of the collagen protein from a T-Rex fossil.
The Organoid Company will use the fragment to recreate what the full-length T-Rex collagen would have looked like, then convert it into a DNA sequence and engineer it into the Lab-Grown Leather cell line genome. If all goes well, it should produce a dense network of T-Rex collagen, similar to a dermis.
The dermis is the structural part of skin, which is all that remains after tanning, so the process should re-create T-Rex leather.
Thomas Mitchell, the chief executive of The Organoid Company, added: 'This project is a remarkable example of how we can harness cutting-edge genome and protein engineering to create entirely new materials.
'By reconstructing and optimising ancient protein sequences, we can design T-Rex leather, a biomaterial inspired by prehistoric biology, and clone it into a custom-engineered cell line.'
'Ground-breaking collaboration'
Fossils suggest that T-Rex skin was scaly, rather than having feathers like many dinosaurs, so the result is likely to be close to that of modern reptiles.
The experts are working alongside VML, a Netherlands-based innovation company, which helped to create the first meatball made from the DNA of a woolly mammoth in 2023.
The team took the DNA sequence for mammoth myoglobin, a key muscle protein in giving meat its flavour, and filled in the gaps using elephant DNA.
'With T-Rex leather, we're harnessing the biology of the past to create the luxury materials of the future,' said Bas Korsten, the global chief creative officer at VML.
'This ground-breaking collaboration represents the intersection of creative innovation and cutting-edge biotechnology, much like we did with our mammoth meatball project.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Metro
6 days ago
- Metro
70,000,000-year-old dinosaur could unlock key cancer discoveries
Scientists believe they could develop new cancer treatments by studying the disease in the remains of prehistoric creatures. Researchers discovered structures similar to red blood cells in dinosaur fossils, which they believe could help better understand tumours and even give rise to new treatments. The ten-year study at Anglia Ruskin University was launched following the discovery of a fossil of a herbivorous Telmatosaurus transsylvanicus – known as a 'marsh lizard' – in Romania with a tumour in its jaw in 2016. Oncologist Professor Justin Stebbing led researchers in a project to see if any parallels could be drawn between the tumour and human cancers. Cancer specialist Dr Biancastella Cereser was part of the team of scientists that conducted a study into the unusual fossil. She told the Independent: 'We contacted the town in Romania, which was very excited to loan us the fossil.' The team then used a 'very, very, very fine drill' and a microscope to look inside the specimen, where they found structures resembling human red blood cells. The development has helped researchers understand 'the role of environment on cancer', Professor Stebbing said. He added that understanding the disease from a 'very ancient perspective' is another piece in the jigsaw. The project in some ways bears a similarity to that of the upcoming Jurassic World movie, which is due to be released in cinemas on July 2. The fourth film in the series follows a group of scientists trying to locate the remains of prehistoric species on an Atlantic island in a bid to create a life-saving drug for humans. More Trending However, after getting stranded on the island, the team discovers it is home to the results of failed dinosaur experiments which have been thriving for decades. They encounter some frightening mutations such as a Distortus Rex – a deformed, alien-like version of a T-Rex with six limbs. But while the claim that dinosaurs can be somewhat resurrected using DNA from their fossils is inaccurate, Professor Stebbing says the discovery of proteins in soft tissues means prehistoric remains could help with the development of better treatments in the future. Get in touch with our news team by emailing us at webnews@ For more stories like this, check our news page. MORE: Diarrhea left me in hospital – but I never expected my diagnosis MORE: Biden jokes he 'can beat the hell out of' authors on his decline after cancer diagnosis MORE: Adele Roberts facing fresh health issue three years after being declared cancer-free
The Sun
6 days ago
- The Sun
Cancer treatment turbocharges patients' own blood cells to kill solid tumours for first time
A LIVING cancer drug has been proven to work against solid tumours for the first time. Immune-boosting CAR-T therapy removes a patient's white blood cells and engineers them into highly specialised cancer killers in a lab. 1 They are then injected back into the patient and let loose against the disease. It is currently only used for blood cell cancers like leukaemia but research by Peking University in China has found it can also work against tumours that form as lumps. In a study of 266 people with stomach cancer, patients who received the treatment survived an average of 7.9 months compared to 5.5 months without it. It took 3.3 months for their cancer to worsen, compared to 1.8 months without. Study author Dr Changsong Qi said the results showed a 'significant increase in progression-free survival and clinically meaningful increase in overall survival'. More than 90 per cent of cancers are solid tumours that grow as a physical mass, including the big four of bowel, breast, lung and prostate. The findings raise the hope that tens or even hundreds of thousands more patients will one day benefit from the pioneering approach using their own immune systems instead of harsh drugs. 'Groundbreaking milestone' Dr Carl June, of the University of Pennsylvania, is credited with inventing the therapy and commented: 'This is a groundbreaking milestone for the field of CAR-T therapies against solid tumours.' CAR-T therapy, full name chimeric antigen receptor T-cell therapy, is an advanced type of immunotherapy that turbocharges the body's own defences to fight off cancer. It is intended to be more accurate and cause less collateral damage and side effects by only attacking cancerous cells and not healthy ones. Sun Health Explainer: What is cancer? Young Sunderland fan Bradley Lowery took part in a major clinical trial of it in 2017 before dying from neuroblastoma aged six. It is currently available on the NHS in England for certain types of leukaemia and lymphoma. More than 650 forms of the treatment are now in development for solid cancers. Dr John Haanen, from the Netherlands Cancer Institute, said: 'There is clearly now evidence that this treatment can benefit patients with solid cancers. It is an important development.' The study was published in The Lancet and presented at the conference of the American Society for Clinical Oncology. Dr Catherine Elliott, of Cancer Research UK, said: 'This is an encouraging early sign and further trials will now be needed.'
Reuters
6 days ago
- Reuters
Gilead's CAR-T cell therapy shows promise in deadly brain cancer
CHICAGO, June 1 (Reuters) - A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent glioblastoma, a rare event for a fatal brain cancer with few treatment options, researchers reported on Sunday. The study, presented at the American Society of Clinical Oncology meeting in Chicago and published in Nature Medicine, is the latest among several efforts testing next-generation chimeric antigen receptor T-cell or CAR-T treatments, a type of immunotherapy in which patients' immune cells are engineered to recognize and kill cancer cells. The work, from researchers at the University of Pennsylvania and Gilead's (GILD.O), opens new tab Kite cell therapy unit, tested a dual CAR-T treatment in an effort to overcome the defenses of glioblastoma, the most common brain tumor in adults. CAR-T therapy is already used to treat blood cancers including leukemia, lymphoma and multiple myeloma, and those treatments typically only take aim at one target on the tumor. But solid tumors such as glioblastoma tend to have multiple subpopulations of tumor cells, suggesting that treatments will need more than one target to succeed, said University of Pennsylvania researcher Dr. Stephen Bagley, who led the study. For the treatment, which is injected directly into spinal fluid, the team selected EGFR, which is found in 50% to 60% of all glioblastoma tumors, and a second target called interleukin-13 receptor alpha 2, found in an estimated 75% of glioblastoma tumors. Typically, advanced glioblastoma patients whose cancers return after initial treatment with surgery, radiation and chemotherapy live six to 10 months. Interim results of just six patients were published in March 2024 in Nature Medicine, opens new tab. The current study now includes 18 patients treated with the experimental therapy after their tumors returned following standard treatment. Of these, only 13 had a measurable tumor at the time the cells were introduced, and of those, eight, or 62%, had their tumors shrink, Bagley said. "That was pretty remarkable to us because historically for recurrent glioblastoma tumors, we usually don't see anything shrink them." Several patients lived 12 months or longer, and in one patient, the disease remained stable for 16 months. But so far, the benefit is largely temporary, with many patients relapsing two to three months later. Most patients experienced fevers and neurotoxicity such as lethargy or confusion for two or three days after the cells are injected, but the side effects were manageable, Bagley said. Cindy Perettie, executive vice president of Gilead's Kite cell therapy unit, said she is encouraged by the 62% response. "What we didn't see that we wanted to in a majority of the patients was persistence," she said. Kite is working to develop a third target that will allow the drug to remain in the brain longer. "We will be putting that construct into the clinic sometime next year," she said. Meanwhile, the team wants to test the therapy in 12 patients with newly diagnosed disease. "We know patients in the frontline setting are going to be healthier," she said, and the hope is to see more persistent results. Demand for the trial has been great. Perettie estimates there are 10 times as many patients seeking enrollment for every open slot, and some doctors are referring patients from as far away as Hawaii. "Today, there's only one approved therapy outside of radiation, so for these patients, this is really exciting to see any kind of response," she said. Kite hopes to expand to three or four centers with its triple-target version of the product. "I think we're on the right track," Bagley said, adding that he believes there will be longer-lasting treatments in the next few years.
